Russell Cohen (University of Chicago Medicine, Chicago, IL, US) spoke with touchIMMUNOLOGY around the optimal use of available therapies in the treatment of IBD. ‘Positioning Tofacitinib and Other Available Therapies’ was presented at the virtual 2021 Crohn’s & Colitis Congress, 21-24 January, 2021.
- Could you tell us a little about tofacitinib and its available formulations? (0:15)
- What key messages would you like to give to physicians regarding the optimal use of tofacitinib in the treatment of IBD? (0:57)
- What other JAK inhibitors are available or in clinical development for IBD? (1:56)
- What is the current status of S1P1 inhibitors in IBD and in which patients should they be considered? (2:54)
- Could you tell us a little about aprelimast and the potential of anti-phosphodiesterase therapy in IBD? (4:20)
Disclosures: Speaker’s Bureau for Abbvie and Takeda; Consultant / Advisory/ Scientific Advisory Board for Abbvie Laboratories, BMS/ Celgene, Eli Lilly, Gilead Sciences, Janssen, Pfizer, Takeda and UCB Pharma; Clinical Trials /Grants (Principal Investigator; active) for Abbvie, BMS/Celgene, Boehringer Ingelheim, Crohn’s & Colitis Foundation of America, Genentech, Gilead Sciences, Hollister, Medimmune, Mesoblast Ltd., Osiris Therapeutics, Pfizer, Receptos, RedHill Biopharma, Sanofi-Aventis, Schwarz Pharma, Seres Therapeutics, Takeda Pharma, and UCB Pharma.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of CCC 2021 (Virtual).
Share this Video
Related Videos In Inflammatory Bowel Disease
Detlef Schuppan, UEG 2021: Transglutaminase 2 Inhibitor in Celiac Disease
touchIMMUNOLOGY caught up with Prof. Detlef Schuppan (Mainz University Medical Center, Mainz, Germany) to talk about the results for the phase 2 study investigating the oral transglutaminase 2 inhibitor, ZED1227, in patients with celiac disease. His presentation entitled ‘ORAL INHIBITOR OF TISSUE TRANSGLUTAMINASE PREVENTS MUCOSAL DAMAGE IN CELIAC PATIENTS UNDERGOING GLUTEN CHALLENGE’ was given at […]
Detlef Schuppan, UEG 2021: Advances in the Management of Celiac Disease
It was a pleasure to catch up with Prof. Detlef Schuppan (Mainz University Medical Center, Mainz, Germany) following his presentations at virtual UEG week to discuss the current unmet needs in the treatment of celiac disease and advances being made in its management. His presentation entitled ‘ORAL INHIBITOR OF TISSUE TRANSGLUTAMINASE PREVENTS MUCOSAL DAMAGE IN […]
Marc Ferrante, UEG 2021: Filgotinib SELECTION Study Results in Ulcerative Colitis
touchIMMUNOLOGY were delighted to speak with Dr Marc Ferrante (University Hospital Leuven, Leuven, Belgium) about the results from the phase 2B/3 study of filgotinib in patients with ulcerative colitis as well as the use of the Partial Mayo Clinical Score in measuring outcomes. His presentation entitled ‘EARLY ACHIEVEMENT OF PARTIAL MAYO SCORE REMISSION AND IBDQ […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!